Michael Gelband’s Seres Therapeutics MCRB Stock Holding History

Michael Gelband’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,737	Closed	-$190K	–	1877
2025 Q4	$190K	Buy	+12,737	New	+$222K	﹤0.01%	1391
2024 Q1	–	Sell	-3,037	Closed	-$85K	–	1776
2023 Q4	$85K	Sell	3,037 -33,746	-92%	-$886K	﹤0.01%	1359
2023 Q3	$1.75M	Buy	36,783 +7,038	+24%	+$537K	0.02%	715
2023 Q2	$2.85M	Buy	+29,745	New	+$3.24M	0.02%	667
2023 Q1	–	Sell	-2,160	Closed	-$242K	–	1984
2022 Q4	$242K	Buy	+2,160	New	+$290K	﹤0.01%	1413
2022 Q3	–	Sell	-830	Closed	-$57K	–	2128
2022 Q2	$57K	Sell	830 -5,516	-87%	-$475K	﹤0.01%	1790
2022 Q1	$904K	Buy	6,346 +1,955	+45%	+$301K	0.01%	1223
2021 Q4	$732K	Buy	+4,391	New	+$698K	0.01%	1233
2021 Q1	–	Sell	-2,331	Closed	-$1.14M	–	2400
2020 Q4	$1.14M	Buy	+2,331	New	+$1.37M	0.01%	788

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's MCRB Position: Q1 2026 in Review

Michael Gelband sold out of Seres Therapeutics (MCRB) in Q1 2026, closing a stake of 12,737 shares — an estimated $190K sold.

Michael Gelband first reported a position in MCRB in Q4 2020 and held it in 9 quarters. The position peaked at $2.85M in Q2 2023. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

Michael Gelband reported no remaining Seres Therapeutics position as of Q1 2026 after selling out during the quarter.
Michael Gelband sold 12,737 Seres Therapeutics shares in Q1 2026, an estimated $190K.
Michael Gelband first reported a position in Seres Therapeutics in Q4 2020 and held it in 9 quarters.
Michael Gelband's Seres Therapeutics position peaked at $2.85M in Q2 2023.
33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.